Our team seeks first to understand you. We ensure all of our team members understand the big picture and the details about your needs, your audiences, and the systems and pressures you may be navigating. We have decades of experience in solving these types of challenges for your peers and in organizations like yours.
When you work with our team, there will be no mysteries or even “secret sauce.” While our ideas may be developed with a unique combination of effort and experience, we make sure our work plans and budgets are transparent to you. As we develop and revise plans, we will show our work and keep you up to date. As your needs and situations change, we’ll quickly adjust and bring new ideas for consideration.
- Research-Informed Creativity and Strategy
- Accurate and Engaging Content and Dissemination
- Digital and Language Accessibility
- Unique Tools for Direct Audience Research
- Qualitative and Quantitative Audience Research
- UX Research and Testing
- Quantitative Research Tools
- Analytics and Measurement
- Program Evaluation
- QDS Research Tool
- Message Development
- Communications Planning
- Health and Science Content
- Media and Digital Dissemination Plans
- Partnership Development and Outreach
- Brand and Identity Development
- Videos and Animation
- Digital and UI Design
- Data Visualization
- Materials Development
Digital Strategy and Development
- UX Research and Strategy
- Open Source CMS Website Development
- Website Content Management
Event Planning and Meeting Coverage
- In-Person and Virtual Meeting Planning
- Scientific Meeting Summaries
National Cancer Institute’s President’s Cancer Panel Report
The President’s Cancer Panel (PCP) was established by Congress in 1971 as a part of the National Cancer Act. The Panel, whose members are appointed by the President of the United States, functions by monitoring development and execution of the National Cancer Program and annually reports to the President on barriers to progress in reducing the burden of cancer. The Panel convenes a series of meetings focused on a specific topic relevant to reducing the burden of cancer and gathers stakeholder input. Annually, the Panel submits a report and makes recommendations for improvements in the National Cancer Program. Lumina Corps serves as a contact and liaison with virtually every facet of the cancer community—researchers, physicians, advocacy organizations, universities, cancer centers, and the public. Our team provides planning and logistical support for each meeting, and assists in preparing the PCP’s Annual Report to the President and in developing journal articles, press releases, and special communication pieces for publication. A diverse range of topics relative to the National Cancer Program are addressed, including Improving Cancer-Related Outcomes with Connected Health; Cancer Communication in the Digital Era: Opportunities and Challenge; Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer.
- Our team assists the Panel and NCI Executive Secretary with concept research and development, and identification (through targeted outreach) and recruitment of a wide range of stakeholders who participate and provide input on selected topics of importance to the National Cancer Program. This has included engaging members of the public and representatives of marginalized populations to testify before the Panel and at town hall meetings hosted by the Panel.
- We provide meeting and logistics services including planning, writing, website, and administrative support for four or more meetings per year including site selection, invitations and registration website, briefing books and other meeting materials. We manage travel and lodging for all participants; provide onsite support, including meeting room setup, and on-site accessibility for those with disabilities.
- Lumina Corps team members plan, write, and design the Panel’s Annual Report to the President (print and 508-compliant digital versions), timed with the online release and media activities.
National Institute on Aging, Division of Neuroscience (NIA DN/NIH)
The Division of Neuroscience’s Alzheimer’s Disease Sequencing Project (ADSP) aims to identify gene alleles contributing to increased risk for or protection against AD, provide insight as to why individuals with known risk factor genes do not develop AD, and identify potential avenues for therapeutic approaches and prevention of the disease. The Alzheimer’s Disease Genetics Consortium (ADGC) conducts genome-wide association studies to identify genes associated with an increased risk of developing late-onset AD. Lumina Corps supports the NIA ADSP and other AD-related initiatives with meeting planning and science writing.
- Lumina Corps provides accurate, timely scientific writing support to more than 1,000 NIA scientific video conferences and program meetings including annual face-to-face sessions.
- Lumina Corps logistical support staff and science writers provide consortium meetings planning and logistical onsite support, attend, audio record and providing writing support for 30 ADGC scientific presentations per year on the NIH campus or through video conference.
National Cancer Institute Center to Reduce Cancer Health Disparities/National Institutes of Health (NCI CRCHD/NIH) Screen to Save (S2S) Initiative
Increasing colorectal cancer (CRC) screening rates is one of the ten recommendations of the Blue Ribbon Panel for the Cancer Moonshot and endorsed by the National Cancer Advisory Board. In response to these recommendations, the Center to Reduce Cancer Health Disparities launched the national Screen to Save (S2S): NCI Colorectal Cancer Outreach and Screening Initiative.
S2S aims to increase CRC screening rates among men and women aged 50 and older from racially and ethnically diverse and rural communities, including: American Indians and Alaskan Natives, Asians, blacks/African Americans, Hispanics/Latinos, and Native Hawaiians and other Pacific Islanders.
Through S2S, community health educators, funded by CRCHD’s National Outreach Network (NON) and Partnerships to Advance Cancer Health Equity (PACHE), provide culturally tailored, evidence-based CRC information, education, and screening resources within racially and ethnically diverse and rural communities nationwide.
Our team took a lead role in developing various data collection instruments for this national initiative. The surveys captured screening and family history, knowledge of CRC and its risk factors and screening options as well as intentions for CRC screening. At study completion, the team will collaborate with CRCHD staff to provide each of the participating sites a site-specific dataset for its own use and analysis and will take a lead role in analyzing aggregated multi-site data. Baseline data has already led to two presentations at the annual meeting of the American Public Health Association (APHA), and the ongoing CRCHD efforts to complete a draft of an S2S manuscript for submission to a peer-reviewed journal.
National Cancer Institute, Center to Reduce Cancer Health Disparities/National Institutes of Health (NCI CRCHD/NIH) Patient Navigation Research Program (PNRP)
The Patient Navigation Research Program (PNRP) aimed to reduce health disparities in the timely delivery of standard cancer care services after cancer screening detected an abnormal finding. Lumina Corps supported the program by evaluating care pathways, helping to identify barriers to timely care, and documenting best practices and lessons learned.
- Our team developed and implemented a comprehensive program evaluation plan including a logic model, conceptual framework, and core data elements for the evaluation. Many patients with cancer identified financial problems and health comorbidities as main barriers to healthcare access, and patients with abnormal screens identified language/interpreter issues as their main barriers.
- We assessed the extent to which PNRP grantee sites were achieving PNRP goals and objectives and the quality of their accomplishments with quantitative and qualitative data collection and analysis. Evaluation findings demonstrated that the program was able to decrease the time typically taken for patients to receive a diagnostic resolution and increased rates of treatment initiation among patient cohorts who otherwise failed to begin treatment within 90 days of a cancer diagnosis.